American Journal of Clinical Dermatology

, Volume 16, Issue 6, pp 457–461 | Cite as

New and Emerging Treatments for Rosacea

  • Lauren M. GoldEmail author
  • Zoe Diana Draelos
Leading Article


Rosacea is a common chronic inflammatory disorder that affects approximately 16 million Americans. The multifactorial pathophysiology of rosacea is not fully understood. Several new treatment options were recently US Food and Drug Administration approved or are in clinical trials. This paper reviews new treatment options including ivermectin, brimonidine, the new foam formulation of azelaic acid, and oxymetazoline. The potential role in therapy, patient selection, and adverse effects of these agents are discussed.


Ivermectin Skin Irritation Rosacea Azelaic Acid Brimonidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Compliance with Ethical Standards


No funding was received for the preparation of this manuscript. Zoe Draelos has received payments for research from Bayer and Galderma.

Conflict of interest

Lauren Gold has no conflicts of interest.


  1. 1.
    Baldwin H. Psychosocial implications of rosacea. Dermatologist. 2012;Suppl.:2–4.Google Scholar
  2. 2.
    Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Gupta MA, Gupta AK, Chen SJ, Johnson AM. Comorbidity of rosacea and depression: an analysis of the National Ambulatory Medical Care Survey and National Hospital Ambulatory Care Survey: Outpatient Department data collected by the U.S. National Center for Health Statistics from 1995 to 2002. Br J Dermatol. 2005;153(6):1176–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Moustafa F, Lewallen RS, Feldman SR. The psychological impact of rosacea and the influence of current management options. J Am Acad Dermatol. 2014;71(5):973–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Layton A, Thiboutot D. Emerging therapies in rosacea. J Am Acad Dermatol. 2013;69(6 Suppl 1):S57–65.CrossRefPubMedGoogle Scholar
  6. 6.
    Del Rosso JQ, Gallo RL, Tanghetti E, Webster G, Thiboutot D. An evaluation of potential correlations between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis. 2013;91(3 Suppl):1–8.PubMedGoogle Scholar
  7. 7.
    Del Rosso JQ, Gallo RL, Kircik L, et al. Why is rosacea considered to be an inflammatory disorder? The primary role, clinical relevance, and therapeutic correlations of abnormal innate immune response in rosacea-prone skin. Drugs Dermatol. 2012;11:694–700.Google Scholar
  8. 8.
    Steinhoff M, Buddenkotte J, Aubert J, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:2–11.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, et al. A status report from the American acne & rosacea society part one: disease state overview, general measures, topical therapy. Consensus recommendations on the management of rosacea. Cutis. 2013;92(5):234–40.PubMedGoogle Scholar
  10. 10.
    Two AM, Wu W, Gallo R, Hata T. Part I: introduction, categorization, histology, pathogenesis, and risk factors. J Am Acad Dermatol. 2015;72:749–58.CrossRefPubMedGoogle Scholar
  11. 11.
    Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435–42.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Wise RD. Submicrobial doxycycline and rosacea. Compr Ther. 2007;33:78–81.CrossRefPubMedGoogle Scholar
  13. 13.
    Merck & Co. Inc. Stromectal (ivermectin) tablets. 2010. Available from: Accessed 21 June 2015.
  14. 14.
    Khan I, Yasmin R. Ivermectin in the treatment of scabies. J Pakistan Assoc Dermatol. 2007;17:78–83.Google Scholar
  15. 15.
    Yanagihara K, Kadoto J, Kohno S. Diffuse panbronchiolitis: pathophysiology and treatment mechanisms. Int J Antimicrob Agents. 2001;18(Suppl 1):S83–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther. 2000;292(1):156–63.PubMedGoogle Scholar
  17. 17.
    Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol. 2009;23:449–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1 % cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13:316–23.PubMedGoogle Scholar
  19. 19.
    Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J. Long-term safety of ivermectin 1 % cream vs azelaic acid 15 % gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol. 2014;13:1380–6.Google Scholar
  20. 20.
    Taieb A, Ortonne JP, Ruzicka T, Roszkiewicz J, Berth-Jones J, Peirone MH, et al. Superiority of ivermectin 1 % cream over metronidazole 0.75 % cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol. 2015;172(4):1103–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Draelos ZD, Elewski B, Staedtler G, Havlickova B. Azelaic acid foam 15 % in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study. Cutis. 2013;92:306–17.PubMedGoogle Scholar
  22. 22.
    Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, Steinhoff M, Rudisill D, Leoni M. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650–6.PubMedGoogle Scholar
  23. 23.
    Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, Swinyer L, Liu H, Leoni M. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5 for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56–61.PubMedGoogle Scholar
  24. 24.
    Tanghetti EA, Jackson JM, Belasco KT, Friedrichs A, Hougier F, Johnson SM, Kerdel FA, Palceski D, Hong HC, Hinek A, Cadena MJ. J Optimizing the use of topical brimonidine in rosacea management: panel recommendations. Drugs Dermatol. 2015;14(1):33–40.Google Scholar
  25. 25. Safety and efficacy of AGN-199201 in patients with persistent erythema associated with rosacea. Available at: Accessed 21 June 2015.
  26. 26.
    Galderma. Soolantra package insert, 2014. Available at: Accessed 8 Sept 2015.
  27. 27.
    Bayer. Finacea foam, 15 % package insert, 2015. Available at: Accessed 8 Sept 2015.

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Henry Ford HospitalDetroitUSA
  2. 2.Dermatology Consulting ServicesHigh PointUSA

Personalised recommendations